Mizuho Turns Bearish on NXP: Auto Exposure and Weak 2026 Outlook Cited
Mizuho cut NXP to sell, slashing target to $188 on weak car demand and high inventory.
Already have an account? Sign in.
Mizuho cut NXP to sell, slashing target to $188 on weak car demand and high inventory.
Kura Oncology’s combo drug shrank kidney tumors in early trial, controlled cancer in most patients, stock jumped.
Affirm is viewed as a strong buy with solid growth, stable funding, and potential upside as positive updates are expected soon.
Goldman sees Corvus as a buy: its oral eczema drug could rival Dupixent and grow into multiple diseases, boosting the stock potential.